Ingredient or product comparison
Cartalax for Anti-Aging: Peptide Comparison
Cartalax is one peptide in a broader category of bioregulators. Understanding where it fits relative to other thymic and immune peptides clarifies which mechanisms it addresses. And which it doesn't. Cartalax (Ala-Glu) Thymus epithelial cells Chromatin remodel
This source-based comparison does not add ratings or recommend a winner.
- Cartalax is one peptide in a broader category of bioregulators. Understanding where it fits relative to other thymic and immune peptides clarifies which mechanisms it addresses. And which it doesn't.
- Cartalax (Ala-Glu)
- Thymus epithelial cells
- Chromatin remodeling to upregulate FOXN1, IL-7, CCL25 in aging TECs
- 10–20 mcg/day SC for 10 days, repeat every 3–4 months
- Russian clinical trials (n>1,200); limited Western validation
- Best-studied bioregulator for thymic function; evidence is institutional but consistent
- Thymalin
- T-lymphocytes and thymic stroma
- Polypeptide extract promoting T-cell differentiation and cytokine signaling
- 10 mg IM daily for 5–10 days
- Russian military and geriatric studies; no FDA trials
- Broader immune support but less tissue-specific than Cartalax
- Thymosin Alpha 1 Peptide
- Dendritic cells and T-cells
- TLR agonism and Th1 cytokine enhancement
- 1.6–3.2 mg SC twice weekly
- FDA-approved in 35+ countries for HBV, HCV; Phase III melanoma data
- Proven immunomodulator but targets active infection/cancer, not aging per se
- Epithalon Peptide (Epitalon)
- Pineal gland and telomeres
- Telomerase activation and melatonin regulation
- 10 mg/day for 10–20 days cyclically
- Animal longevity data strong; human data limited to biomarker studies
- Theoretical geroprotector with telomere evidence; lacks immune-specific outcomes
- Semax Amidate Peptide
- Central nervous system
- BDNF upregulation and neurotrophin signaling
- 300–600 mcg intranasal daily
- Russian stroke/TBI trials; nootropic use widespread
- Neuro-focused. No thymic or immune target overlap with Cartalax
- Cartalax for anti-aging sits in a unique position: it's tissue-specific (thymus), mechanism-specific (chromatin remodeling), and has consistent but geographically isolated clinical evidence. It's not a cure-all longevity peptide. It addresses one measurable aspect of immune aging with a defined protocol and reproducible outcomes.